The estimated Net Worth of Andrei V Gudkov is at least $5.01 Milione dollars as of 17 May 2010. Andrei Gudkov owns over 5,000 units of Cytocom Inc stock worth over $4,769,582 and over the last 17 years he sold CBLI stock worth over $173,507. In addition, he makes $66,138 as Chief Scientific Officer at Cytocom Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Andrei Gudkov CBLI stock SEC Form 4 insiders trading
Andrei has made over 10 trades of the Cytocom Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of CBLI stock worth $17,650 on 17 May 2010.
The largest trade he's ever made was selling 5,000 units of Cytocom Inc stock on 17 May 2010 worth over $17,650. On average, Andrei trades about 2,500 units every 14 days since 2008. As of 17 May 2010 he still owns at least 1,504,600 units of Cytocom Inc stock.
You can see the complete history of Andrei Gudkov stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Andrei Gudkov biography
Dr. Andrei V. Gudkov Ph.D. serves as Chief Scientific Officer of the Company. Dr. Gudkov served as Senior Vice President of Basic Science at Roswell Park Comprehensive Cancer Center (Roswell Park) and since 2019 he has served as Senior Vice President of Research Technology and Innovation at Roswell Park. Since 2007, he has served as Chairman of the Department of Cell Stress Biology at Roswell Park. He also serves as a Director for Everon Biosciences, Inc., Oncotartis Inc., Incuron Inc., Panacela Labs, Inc., and Chief Science Officer of Genome Protection, Inc., an anti-aging drug development company jointly owned by the Company. From 2001 to 2007, he was Chairman of the Department of Molecular Biology at the Lerner Research Institute at the Cleveland Clinic and Professor of Biochemistry at Case Western Reserve University. Prior to this, he was a tenured faculty member in the Department of Molecular Genetics at the University of Illinois at Chicago, where his lab concentrated on the development of new functional gene discovery methodologies and the identification of new candidate cancer treatment targets. Before immigrating to the United States in 1990, Dr. Gudkov worked at The National Cancer Research Center in Moscow, where he led a broad research program focused on virology and cancer drug resistance. Dr. Gudkov holds a Ph.D. and D. Sci. Degree in Experimental Oncology from the Cancer Research Center (Moscow, Russia).
What is the salary of Andrei Gudkov?
As the Chief Scientific Officer of Cytocom Inc, the total compensation of Andrei Gudkov at Cytocom Inc is $66,138. There are 2 executives at Cytocom Inc getting paid more, with Christopher Zosh having the highest compensation of $103,494.
How old is Andrei Gudkov?
Andrei Gudkov is 64, he's been the Chief Scientific Officer of Cytocom Inc since 2003. There are 1 older and 7 younger executives at Cytocom Inc. The oldest executive at Cytocom Inc is Langdon Miller, 66, who is the President, Chief Medical Officer.
What's Andrei Gudkov's mailing address?
Andrei's mailing address filed with the SEC is 73 HIGH STREET, , BUFFALO, NY, 14203.
Insiders trading at Cytocom Inc
Over the last 17 years, insiders at Cytocom Inc have traded over $1,157,190 worth of Cytocom Inc stock and bought 66,403 units worth $199,902 . The most active insiders traders include James Antal, Michael Fonstein e Bernard L Kasten. On average, Cytocom Inc executives and independent directors trade stock every 101 days with the average trade being worth of $21,921. The most recent stock trade was executed by Langdon L Miller on 22 July 2021, trading 10,000 units of CBLI stock currently worth $30,000.
What does Cytocom Inc's logo look like?
Complete history of Andrei Gudkov stock trades at Cytocom Inc
Cytocom Inc executives and stock owners
Cytocom Inc executives and other stock owners filed with the SEC include:
-
Christopher Zosh,
Interim Principal Executive Officer and Principal Financial Officer, Vice President of Finance -
Langdon Miller,
President, Chief Medical Officer -
Andrei Gudkov,
Chief Scientific Officer -
Lea Verny,
Independent Chairman of the Board -
Daniil Talyanskiy,
Independent Director -
Randy Saluck,
Independent Director -
Anna Evdokimova,
Independent Director -
Alexander Andryushechkin,
Independent Director -
Ivan Fedyunin,
Independent Director -
Anthony Principi,
Director -
C Neil Lyons,
Chief Financial Officer -
Elena Kasimova,
Director -
Yakov Kogan,
EVP of Bus. Development, Sec. -
Richard Mc Gowan,
Director -
James Antal,
Director -
Daniel Floyd Jr Hoth,
Director -
Julia R Brown,
Director -
Alexander Polinsky,
Director -
David C Hohn,
Director -
Bernard L Kasten,
Director -
Jean Viallet,
Chief Development Officer -
Paul E Di Corleto,
Director -
Michael Fonstein,
CEO & President -
Hector Daniel Perez,
Director -
John A Jr Marhofer,
Chief Financial Officer -
Securities Corp Sunrise,
10% owner -
Michael K Handley,
President and CEO -
Robert Buckheit,
Chief Technology Officer -
Cozette M. Mc Avoy,
Chief Legal Officer -
Clifford Selsky,
Chief Medical Officer -
Peter Aronstam,
Chief Financial Officer